TNF and psoriasis: During a 10-year period, TNF inhibitor–treated patients had a reduced risk of developing any primary malignancy compared with biologic-naïve patients with psoriasis (hazard ratio [HR] = 0.80; 95% confidence interval [CI] = 0.73–0.87).